drugset / Trial / NCT03697655
Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma
Phase 2
Unknown
274 enrolled
Polish Myeloma Consortium
Bioscience, S.A. · collabJanssen-Cilag Ltd. · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
PREDATOR is a study investigating a role of preemptive daratumumab therapy for preclinical relapse or progression of multiple myeloma (MM).
Timeline
- Start
- 2018-12-10
- Primary completion
- 2020-09
- Completion
- 2024-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | 16 mg/kg | Intravenous |